Fabry Disease Treatment Market Highlights:
Fabry disease market is expected to reach USD 3.55 billion by 2030 at CAGR of 7.8% over the figure period 2022-2030. Technological advancements, strong pipeline, advancements in healthcare facilities, and favourable funding policies are expected to drive the market growth over the forecast period. Owing to the increasing awareness about Fabry disease market trends and existing market players are coming up with better treatment approaches. For instance, in 2018, 2018, Amicus Therapeutics launched Gala fold capsules 123mg for the treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.
However, diverse range of symptoms, and related complications can restrain the market growth over the assessment period.
Regional Analysis:
Geographically, the Americas is expected to dominate the global market owing to the increasing technological advancements and rising research and development activities. Gastrointestinal manifestations such as abdominal pain, diarrhoea and nausea are significant burden in a patient with Fabry disease. So, for the advanced treatment of these patients Smart Pill testing procedure is developed to gain additional understanding of Fabry disease manifestation via motility abnormalities to improve symptom targeted therapy. This device is currently under clinical trial and the sponsor of this study is Massachusetts General Hospital.
Europe is expected to hold the second largest market share. Nearly 2.2 in 10,000 people in the European Union (EU) are affected with Fabry disease and Fabrazyme (agalsidase beta), Galafold (migalastat) and Replagal (agalsidase alfa) are the three authorized drugs used for the treatment of Fabry disease.
Asia-Pacific is expected to be the fastest growing market owing to the improving healthcare infrastructure.
Moreover, the Middle East and Africa region is expected to hold the least market share in the global Fabry disease market.
Fabry Disease Market Players
The global Fabry disease market players are Amgen Inc., Amicus Therapeutics, Inc., AVROBIO, Inc., Idorsia Pharmaceuticals Ltd, Protalix, Bristol-Myers Squibb Company, GlaxoSmithKline, iBio, Inc., Neuraltus Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Sanofi, Shire, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd and others.
Segmentation:
The Global Fabry Disease Market insights has been segmented into type, diagnosis & treatment, and end user.
The market, based on type, has been segmented into type-1 and type-2. The type-2 Fabry disease holds the major market share due to the high occurrence of type-2 Fabry disease i.e., 1 in 1,500 to 4000 males.
The market, by diagnosis & treatment, has been segmented into diagnosis and treatment. The diagnosis segment is further classified as blood test, urine test, thyroid test, lung function test, and imaging. The imaging segment includes electrocardiogram (EKG), echocardiogram, brain MRI, CT scan and others. The treatment segment is further classified as enzyme replacement therapy, gene therapy, pharmaceutical formulations containing glissade alfa, analgesics, anticonvulsants, nonsteroidal anti-inflammatory drugs (NSAIDs), and others.
The market, by end user, has been segmented into hospitals & clinics, diagnostic centres, research & academic institutes, and others.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
